CRISPR Therapeutics (NASDAQ:CRSP) Stock Rating Upgraded by StockNews.com

StockNews.com upgraded shares of CRISPR Therapeutics (NASDAQ:CRSP) to a sell rating in a research report report published on Thursday morning.

A number of other brokerages have also issued reports on CRSP. Rodman & Renshaw assumed coverage on shares of CRISPR Therapeutics in a research note on Friday, August 2nd. They issued a “buy” rating and a $90.00 target price on the stock. Cantor Fitzgerald reiterated a “neutral” rating on shares of CRISPR Therapeutics in a report on Thursday, August 8th. Stifel Nicolaus lowered their target price on CRISPR Therapeutics from $60.00 to $59.00 and set a “hold” rating on the stock in a report on Tuesday, August 6th. Truist Financial cut their price objective on CRISPR Therapeutics from $120.00 to $100.00 and set a “buy” rating for the company in a research report on Monday, August 12th. Finally, Barclays dropped their target price on shares of CRISPR Therapeutics from $59.00 to $55.00 and set an “equal weight” rating on the stock in a research report on Wednesday. Three research analysts have rated the stock with a sell rating, eight have given a hold rating and nine have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $74.94.

CRISPR Therapeutics Stock Performance

NASDAQ:CRSP opened at $51.62 on Thursday. CRISPR Therapeutics has a one year low of $43.42 and a one year high of $91.10. The business’s 50-day simple moving average is $47.45 and its 200 day simple moving average is $52.18. The stock has a market cap of $4.41 billion, a price-to-earnings ratio of -18.24 and a beta of 1.67.

CRISPR Therapeutics (NASDAQ:CRSP) last released its earnings results on Tuesday, November 5th. The company reported ($1.01) EPS for the quarter, beating the consensus estimate of ($1.42) by $0.41. The company had revenue of $0.60 million during the quarter, compared to analysts’ expectations of $6.65 million. CRISPR Therapeutics had a negative return on equity of 12.15% and a negative net margin of 118.13%. During the same period in the prior year, the business posted ($1.41) EPS. On average, equities research analysts predict that CRISPR Therapeutics will post -5.47 EPS for the current year.

Insider Activity at CRISPR Therapeutics

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 4,293 shares of the company’s stock in a transaction dated Monday, October 14th. The shares were sold at an average price of $46.28, for a total transaction of $198,680.04. Following the sale, the chief executive officer now directly owns 226,540 shares of the company’s stock, valued at approximately $10,484,271.20. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, General Counsel James R. Kasinger sold 1,089 shares of the company’s stock in a transaction dated Monday, October 14th. The shares were sold at an average price of $46.28, for a total transaction of $50,398.92. Following the transaction, the general counsel now owns 62,597 shares in the company, valued at $2,896,989.16. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Samarth Kulkarni sold 4,293 shares of the stock in a transaction dated Monday, October 14th. The stock was sold at an average price of $46.28, for a total transaction of $198,680.04. Following the sale, the chief executive officer now directly owns 226,540 shares in the company, valued at approximately $10,484,271.20. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 4.10% of the stock is currently owned by insiders.

Hedge Funds Weigh In On CRISPR Therapeutics

A number of large investors have recently modified their holdings of the stock. SFE Investment Counsel raised its position in CRISPR Therapeutics by 3.6% in the 2nd quarter. SFE Investment Counsel now owns 5,846 shares of the company’s stock worth $316,000 after purchasing an additional 203 shares during the last quarter. Northwestern Mutual Wealth Management Co. raised its position in shares of CRISPR Therapeutics by 4.8% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 4,606 shares of the company’s stock worth $249,000 after acquiring an additional 211 shares during the last quarter. Orion Capital Management LLC lifted its stake in shares of CRISPR Therapeutics by 44.0% during the first quarter. Orion Capital Management LLC now owns 720 shares of the company’s stock valued at $49,000 after acquiring an additional 220 shares during the period. National Bank of Canada FI boosted its holdings in CRISPR Therapeutics by 35.0% in the second quarter. National Bank of Canada FI now owns 848 shares of the company’s stock valued at $46,000 after acquiring an additional 220 shares during the last quarter. Finally, Larson Financial Group LLC increased its position in CRISPR Therapeutics by 95.5% in the second quarter. Larson Financial Group LLC now owns 565 shares of the company’s stock worth $31,000 after purchasing an additional 276 shares during the period. 69.20% of the stock is currently owned by institutional investors and hedge funds.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.